EI
RAPT

Ethic Inc’s RAPT Therapeutics RAPT Stock Holding History

Ethic Inc’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,474
Closed -$18.6K – 1211
2024
Q4 		$18.6K Buy
+1,474
New +$18.7K ﹤0.01% 1139

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Ethic Inc's RAPT Position: Q1 2025 in Review

Ethic Inc sold out of RAPT Therapeutics (RAPT) in Q1 2025, closing a stake of 1,474 shares — an estimated $18.6K sold.

Ethic Inc first reported a position in RAPT in Q4 2024 and held it in 1 quarter. The position peaked at $18.6K in Q4 2024. 92 funds tracked by Wall St. Rank hold RAPT as of Q1 2025.

  • Ethic Inc reported no remaining RAPT Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ethic Inc sold 1,474 RAPT Therapeutics shares in Q1 2025, an estimated $18.6K.
  • Ethic Inc first reported a position in RAPT Therapeutics in Q4 2024 and held it in 1 quarter.
  • Ethic Inc's RAPT Therapeutics position peaked at $18.6K in Q4 2024.
  • 92 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2025.

Based on Ethic Inc's 13F filing for Q1 2025, filed 13 May 2025.